Investment

Top Biotech IPOs to Watch in 2025

The biotechnology sector continues to be a focal point for investors seeking groundbreaking innovations and substantial growth opportunities. As we progress through 2025, several biotech companies are preparing to make their debut on the public markets. This article provides an overview of the top biotech IPOs to watch this year, highlighting their key developments, financial health, and potential market impact.

1. Metsera, Inc.

Metsera, founded in 2022 by ARCH Venture Partners and Population Health Partners, has rapidly positioned itself as a notable player in the weight-loss therapeutics arena. The company’s primary focus is on developing both injectable and oral drugs targeting obesity, utilizing the GLP-1 mechanism among other biological pathways. Their lead product candidate, MET-097i, an injectable formulation, demonstrated promising results in mid-stage trials, showing an average weight loss of 11.3% in patients.

AI IPOs: A Five-Year Performance Review and Market Trends

Over the past five years, artificial intelligence (AI) has evolved from a specialized technology into a powerful catalyst reshaping multiple global industries. With AI increasingly integral to innovation and corporate strategy, investor interest in AI-focused IPOs has surged. This article examines the recent financial performance, investor reception, emerging market trends, and the challenges AI companies face within a rapidly changing investment landscape.

The Surge in AI Investments

Significant investments from leading technology firms have fueled rapid advancements in AI. Microsoft’s groundbreaking $10 billion investment in OpenAI in early 2023 set a new standard for corporate AI commitments. Following suit, Amazon injected $4 billion into Anthropic, while Google pledged $2 billion toward Cohere, marking 2024 as a pivotal year for strategic AI investments.